What is Leerink Partnrs’ Estimate for TVTX FY2026 Earnings?

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Analysts at Leerink Partnrs boosted their FY2026 EPS estimates for shares of Travere Therapeutics in a research note issued to investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of $0.52 per share for the year, up from their prior forecast of $0.51. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.93) per share.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.01. The firm had revenue of $62.90 million during the quarter, compared to analyst estimates of $60.87 million. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The business’s revenue was up 69.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.17) EPS.

TVTX has been the subject of a number of other research reports. Wells Fargo & Company raised shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $9.00 to $27.00 in a research report on Monday, October 21st. Cantor Fitzgerald started coverage on shares of Travere Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating on the stock. Leerink Partners reissued an “outperform” rating and issued a $20.00 target price on shares of Travere Therapeutics in a research note on Tuesday, October 8th. Canaccord Genuity Group lowered their target price on shares of Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday, September 30th. Finally, Barclays upped their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, Travere Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $24.00.

Travere Therapeutics Stock Up 5.9 %

Shares of TVTX opened at $19.46 on Tuesday. The company has a 50-day simple moving average of $18.21 and a 200-day simple moving average of $14.72. The firm has a market capitalization of $1.52 billion, a P/E ratio of -4.28 and a beta of 0.70. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. Travere Therapeutics has a 52 week low of $5.12 and a 52 week high of $20.33.

Hedge Funds Weigh In On Travere Therapeutics

Large investors have recently bought and sold shares of the business. CWM LLC lifted its holdings in Travere Therapeutics by 158.5% in the third quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after buying an additional 3,065 shares during the period. Quarry LP acquired a new stake in Travere Therapeutics in the third quarter worth $105,000. Diversified Trust Co acquired a new stake in Travere Therapeutics in the third quarter worth $161,000. DRW Securities LLC acquired a new stake in Travere Therapeutics in the second quarter worth $95,000. Finally, Aigen Investment Management LP acquired a new stake in Travere Therapeutics in the third quarter worth $170,000.

Insider Activity

In related news, insider Jula Inrig sold 2,066 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $19.10, for a total value of $39,460.60. Following the transaction, the insider now directly owns 59,883 shares in the company, valued at $1,143,765.30. This represents a 3.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Sandra Calvin sold 15,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $17.22, for a total transaction of $258,300.00. Following the completion of the transaction, the chief accounting officer now owns 54,927 shares in the company, valued at $945,842.94. This represents a 21.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 29,596 shares of company stock valued at $527,262 over the last three months. 4.06% of the stock is owned by insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.